Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29354115 | 1.00 | ESR1 (1.00) | ESR1ESR2 | |
| SCHEMBL1821303 | 1.00 | ESR1 (1.00) | ESR1ESR2 | |
| SCHEMBL7058506 | 0.99 | ESR1 (0.98) | ESR1ESR2 | |
| SCHEMBL7056839 | 0.97 | ESR1 (0.94) | ESR1ESR2 | |
| SCHEMBL7056486 | 0.95 | ESR1 (0.91) | ESR1ESR2 | |
| SCHEMBL6259524 | 0.92 | ESR1 (0.84) | ESR1ESR2 | |
| SCHEMBL28107129 | 0.92 | ESR1 (0.84) | ESR1ESR2 | |
| SCHEMBL2898159 | 0.92 | ESR1 (0.84) | ESR1ESR2 | |
| SCHEMBL21571869 | 0.91 | ESR1 (0.83) | ESR1ESR2 | |
| SCHEMBL6294980 | 0.90 | ESR1 (0.81) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078114-A1 | COMBINATION THERAPY FOR ALZHEIMER'S DISEASE AND OTHER DISEASES | MYRIAD GENETICS, INCORPORATED (US) | 2007-04-05 | — | — | US | claimed |
| EP-1165061-B1 | USE OF COMPOUND PREPARATION MADE OF VITAMIN D METABOLITES OR VITAMIN D ANALOGUES AND PARTIAL ESTROGEN AGONISTS FOR TREATING OSTEOPOROSIS | SCHERING AG (DE) | 2005-10-19 | — | — | EP | claimed |
| US-20050118600-A1 | Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-02 | — | — | US | claimed |
| EP-3373967-B9 | TREATMENT OF ER-NEGATIVE BREAST CANCER WITH AN PDGF-CC INHIBITOR AND AN ANTI ESTROGEN | PARACRINE THERAPEUTICS AB (SE) | 2023-10-04 | — | — | EP | disclosed |
| EP-3373967-B1 | TREATMENT OF ER-NEGATIVE BREAST CANCER WITH AN PDGF-CC INHIBITOR AND AN ANTI ESTROGEN | PARACRINE THERAPEUTICS AB (SE) | 2023-06-07 | — | — | EP | disclosed |
| US-11633382-B2 | Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and anti-estrogen | PARACRINE THERAPEUTICS AB (SE) | 2023-04-25 | — | — | US | disclosed |
| US-20210186932-A1 | TREATMENT OF ER-NEGATIVE BREAST CANCER WITH AN PDGF-CC INHIBITOR AND ANTI-ESTROGEN | PARACRINE THERAPEUTICS AB (SE) | 2021-06-24 | — | — | US | disclosed |
| EP-3682880-A1 | TREATMENT OF HOT FLUSHES, VASOMOTOR SYMPTOMS, AND NIGHT SWEATS WITH SEX STEROID PRECURSORS IN COMBINATION WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS | Endorecherche, Inc. (CA) | 2020-07-22 | — | — | EP | disclosed |
| US-10342805-B2 | Treatment of Alzheimer's disease, loss of cognition, memory loss and dementia with sex steroid precursors in combination with selective estrogen receptor modulators | ENDORECHERCHE, INC. (CA) | 2019-07-09 | — | — | US | disclosed |
| EP-3373967-A1 | TREATMENT OF ER-NEGATIVE BREAST CANCER WITH AN PDGF-CC INHIBITOR AND AN ANTI ESTROGEN | Paracrine Therapeutics AB (SE) | 2018-09-19 | — | — | EP | disclosed |
| US-9687458-B2 | Trans-clomiphene for use in cancer therapy | REPROS THERAPEUTICS INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-6465445-B1 | SUCH AS DERIVATIVE CONTAINING PHENYL, BENZOPHENONE AND PYRROLIDINE OR PIPERIDINE RINGS AND DEHYDROEPIANDROSTERONE; TREATMENT AND/OR INHIBITION OF OSTEOPOROSIS, BREAST CANCER, HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA OR ATHEROSCLEROSIS | ENDORECHERCHE, INC. (CA) | 2002-10-15 | — | — | US | disclosed |
| US-20020119502-A1 | Combination therapy for the treatment of estrogen-sensitive disease | INTARCIA THERAPEUTICS, INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002030429-A1 | COMBINATION THERAPY FOR THE TREATMENT OF ESTROGEN-SENSITIVE DISEASE | BIOMEDICINES, INC. (US) | 2002-04-18 | — | — | WO | disclosed |
| EP-1167364-A1 | Benzopyran-containing compounds and prodrug forms thereof | Endorecherche Inc. (CA) | 2002-01-02 | — | — | EP | disclosed |
| WO-2001068634-A1 | 4-FLUOROALKYL-2H-BENZOPYRANS WITH ANTI-ESTROGENIC ACTIVITY | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001054699-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS IN COMBINATION WITH ESTROGENS | ENDORECHERCHE, INC. (CA) | 2001-08-02 | — | — | WO | disclosed |
| US-6060503-A | ANTIESTROGENIC, ANTICARCINOGENIC STEREOSPECIFIC BENZOPYRAN DERIVATIVE; BREAST CANCER | ENDORECHERCHE, INC. (CA) | 2000-05-09 | — | — | US | disclosed |
| EP-0811006-A1 | BENZOPYRAN-CONTAINING COMPOUNDS AND METHOD FOR THEIR USE | ENDORECHERCHE INC. (CA) | 1997-12-10 | — | — | EP | disclosed |
| WO-1996026201-A1 | BENZOPYRAN-CONTAINING COMPOUNDS AND METHOD FOR THEIR USE | ENDORECHERCHE, INC. (CA) | 1996-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10342805-B2 | Treatment of Alzheimer's disease, loss of cognition, memory loss and dementia with sex steroid precursors in combination with selective estrogen receptor modulators | BRCA1, SHBG, CYP19A1 | ESR1 5/4885ESR2 6/4885 |
| US-20020119502-A1 | Combination therapy for the treatment of estrogen-sensitive disease | ESR2, ESRRB, ESR1 | ESR1 3/4885ESR2 1/4885 |
| US-20070078114-A1 | COMBINATION THERAPY FOR ALZHEIMER'S DISEASE AND OTHER DISEASES | PSEN2, APP, PSEN1 | ESR1 208/4885ESR2 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.